Severe dermatitis-multiple allergies-metabolic loss syndromeQ80.9

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 17.03.2024

Dieser Artikel auf Deutsch

Synonym(s)

ORPHA:369992; SAM syndrome; SAM Syndrome; SAM syndromes; Severe dermatitis-multiple allergies and metabolically induced failure to thrive; Severe dermatitis, multiple allergies, and metabolic wasting syndrome

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

The "Severe Dermatitis-Multiple Allergies-Metabolic Loss Syndrome" (SAM syndrome) is an extremely rare (only 3 families have been described) genodermatosis. It is characterized by missense mutations occurring in the desmoglein-1 gene (but also in the desmoplakin gene/McAleerMA et al. 2015).

Clinically in the foreground is a pronounced ichthyosiform erythroderma already existing at birth. In addition to chronic cutaneous inflammation(severe dermatitis), transcutaneous sensitization with multiple allergies and severemetabolic wasting occur.

Furthermore, the syndrome is characterized by recurrent skin and respiratory infections and hypotrichosis. In contrast to the clinically related Netherton syndrome in which palmo-plantar keratoses are absent, they are present in SAM syndrome.

Occurrence/EpidemiologyThis section has been translated automatically.

The clinical picture has a prevalence <1 / 1 000 000.

Internal therapyThis section has been translated automatically.

Recently, the IL-17 antibody secukinumab was described as a successful treatment for SAM syndrome (Cao Q et al. 2023).

LiteratureThis section has been translated automatically.

  1. Cao Q et al. (2023) Successful Treatment of SAM Syndrome With Secukinumab Monotherapy: A Case Report of a 16-Month-Old Infant. Dermatitis. doi: 10.1089/derm.2023.0222.
  2. Dereure O (2015) Homozygous desmoglein 1 gene mutations and severe dermatitis, multiple allergies and metabolic wasting (SAM syndrome) Ann Dermatol Venereol 142:798-799.
  3. McAleer MA et al. (2015) Severe dermatitis, multiple allergies, and metabolic wasting syndrome caused by a novel mutation in the N-terminal plakin domain of desmoplakin. J Allergy Clin Immunol 136:1268-1276.
  4. Pan C et al. (2021) Deep-intronic and frameshift DSG1 variants associated with atypical severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome in a Chinese family. Eur J Dermatol 31:239-244.
  5. Samuelov L et al. (2014) Peeling off the genetics of atopic dermatitis-like congenital disorders.J Allergy Clin Immunol 134:808-815.

Authors

Last updated on: 17.03.2024